CN116964045A - 用于治疗与sting活性有关的疾病的草酰胺化合物和组合物 - Google Patents

用于治疗与sting活性有关的疾病的草酰胺化合物和组合物 Download PDF

Info

Publication number
CN116964045A
CN116964045A CN202280019954.XA CN202280019954A CN116964045A CN 116964045 A CN116964045 A CN 116964045A CN 202280019954 A CN202280019954 A CN 202280019954A CN 116964045 A CN116964045 A CN 116964045A
Authority
CN
China
Prior art keywords
group
independently selected
compound
optionally substituted
ring atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280019954.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·范卡彻曼
J·卡茨
W·R·劳世
H·M·塞德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma AG
Original Assignee
Afumdeyou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afumdeyou Co ltd filed Critical Afumdeyou Co ltd
Publication of CN116964045A publication Critical patent/CN116964045A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202280019954.XA 2021-01-08 2022-01-07 用于治疗与sting活性有关的疾病的草酰胺化合物和组合物 Pending CN116964045A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135303P 2021-01-08 2021-01-08
US63/135,303 2021-01-08
PCT/US2022/011551 WO2022150549A1 (en) 2021-01-08 2022-01-07 Oxalamide compounds and compositions for treating conditions associated with sting activity

Publications (1)

Publication Number Publication Date
CN116964045A true CN116964045A (zh) 2023-10-27

Family

ID=80123502

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280019954.XA Pending CN116964045A (zh) 2021-01-08 2022-01-07 用于治疗与sting活性有关的疾病的草酰胺化合物和组合物

Country Status (5)

Country Link
US (1) US20240083879A1 (https=)
EP (1) EP4274826A1 (https=)
JP (1) JP2024502473A (https=)
CN (1) CN116964045A (https=)
WO (1) WO2022150549A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4274824A1 (en) 2021-01-08 2023-11-15 IFM Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
IL310724A (en) 2021-08-10 2024-04-01 Ifm Due Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH STING ACTIVITY
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272763A1 (en) * 2002-08-02 2005-12-08 Toupence Richard B Substituted furo[2,3-b]pyridine derivatives
CN105142634A (zh) * 2013-04-26 2015-12-09 美国印第安纳大学研究和技术公司 包含Src同源-2结构域的致癌性蛋白酪氨酸磷酸酶-2(SHP2)的基于羟基吲哚羧酸的抑制剂
WO2020010092A1 (en) * 2018-07-03 2020-01-09 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2020236586A1 (en) * 2019-05-17 2020-11-26 Ifm Due, Inc. N-hetaryl-squaramide compounds for treating conditions associated with sting activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
MY169791A (en) * 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
US8497285B2 (en) 2010-12-03 2013-07-30 The Trustees Of The University Of Pennsylvania Therapy of autoimmune colitis using a TIP60 inhibitor
CA2927009C (en) 2013-10-21 2019-04-23 Drexel University Use of sting agonists to treat chronic hepatitis b virus infection
WO2021067791A1 (en) * 2019-10-03 2021-04-08 Ifm Due, Inc. Oxalamide compounds and compositions for treating conditions associated with sting activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272763A1 (en) * 2002-08-02 2005-12-08 Toupence Richard B Substituted furo[2,3-b]pyridine derivatives
CN105142634A (zh) * 2013-04-26 2015-12-09 美国印第安纳大学研究和技术公司 包含Src同源-2结构域的致癌性蛋白酪氨酸磷酸酶-2(SHP2)的基于羟基吲哚羧酸的抑制剂
WO2020010092A1 (en) * 2018-07-03 2020-01-09 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2020236586A1 (en) * 2019-05-17 2020-11-26 Ifm Due, Inc. N-hetaryl-squaramide compounds for treating conditions associated with sting activity

Also Published As

Publication number Publication date
JP2024502473A (ja) 2024-01-19
US20240083879A1 (en) 2024-03-14
WO2022150549A1 (en) 2022-07-14
EP4274826A1 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
CN112823151B (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN112823036B (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN115348957B (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN113382772B (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
US12152018B2 (en) Compounds and compositions for treating conditions associated with STING activity
CN116157394A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
EP4182028A1 (en) Compounds and compositions for treating conditions associated with sting activity
CN113874010A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN116261452A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN117222634A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN117480169A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN117561253A (zh) 用于治疗与sting活性有关的病症的化合物和组合物
WO2022015938A1 (en) Compounds and compositions for treating conditions associated with sting activity
US20250136597A1 (en) Compounds and compositions for treating conditions associated with sting activity
CN116964045A (zh) 用于治疗与sting活性有关的疾病的草酰胺化合物和组合物
TW202334084A (zh) 用於治療與sting活性相關之病況的化合物及組合物
CN117321048A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
CN118715205A (zh) 用于治疗与sting活性相关的病症的化合物和组合物
WO2025079045A1 (en) Compounds and compositions for treating conditions associated with sting activity
HK40107971A (zh) 用於治疗与sting活性有关的疾病的化合物和组合物
HK40048003A (en) Compounds and compositions for treating conditions associated with sting activity
HK40048003B (zh) 用於治疗与sting活性有关的疾病的化合物和组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250205

Address after: Basel, SUI

Applicant after: NOVARTIS PHARMA AG

Country or region after: Switzerland

Address before: U.S.A.

Applicant before: Afumdeyou Co.,Ltd.

Country or region before: U.S.A.